Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pinky Dua

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Interface Focus|January 16, 2014
Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacologyNeil Benson, Tomomi Matsuura, Sergey Smirnov, et al.
British Journal of Clinical Pharmacology|November 28, 2017
Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain modelsPeter Loudon, Pieter Siebenga, Donal Gorman, et al.
European Journal of Pain (London, England)|February 23, 2019
Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugsPieter S Siebenga, Guido van Amerongen, Pieter Okkerse, et al.
The Lancet. Neurology|January 10, 2012
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trialDavid H Miller, Thomas Weber, Richard Grove, et al.
British Journal of Anaesthesia|March 28, 2019
Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABA<sub>A</sub> partial agonist, in humansGuido van Amerongen, Pieter S Siebenga, Rachel Gurrell, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentJagdev S Sidhu, Maria Luisa Sardu, Marcus A Björnsson, et al.
Gene Therapy|November 5, 2021
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophyVahid Farrokhi, Jason Walsh, Joe Palandra, et al.
Pharmacology Research & Perspectives|February 21, 2019
Phase I study of PF‐04895162, a Kv7 channel opener, reveals unexpected hepatotoxicity in healthy subjects, but not rats or monkeys: clinical evidence of disrupted bile acid homeostasisMichael D Aleo, Jiri Aubrecht, Paul D Bonin, et al.
British Journal of Pharmacology|December 8, 2017
Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA<sub>A</sub> receptor positive allosteric modulator PF-06372865Sarah A Nickolls, Rachel Gurrell, Guido van Amerongen, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Interface Focus|January 16, 2014
Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacologyNeil Benson, Tomomi Matsuura, Sergey Smirnov, et al.
British Journal of Clinical Pharmacology|November 28, 2017
Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain modelsPeter Loudon, Pieter Siebenga, Donal Gorman, et al.
European Journal of Pain (London, England)|February 23, 2019
Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugsPieter S Siebenga, Guido van Amerongen, Pieter Okkerse, et al.
The Lancet. Neurology|January 10, 2012
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trialDavid H Miller, Thomas Weber, Richard Grove, et al.
British Journal of Anaesthesia|March 28, 2019
Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABA<sub>A</sub> partial agonist, in humansGuido van Amerongen, Pieter S Siebenga, Rachel Gurrell, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentJagdev S Sidhu, Maria Luisa Sardu, Marcus A Björnsson, et al.
Gene Therapy|November 5, 2021
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophyVahid Farrokhi, Jason Walsh, Joe Palandra, et al.
Pharmacology Research & Perspectives|February 21, 2019
Phase I study of PF‐04895162, a Kv7 channel opener, reveals unexpected hepatotoxicity in healthy subjects, but not rats or monkeys: clinical evidence of disrupted bile acid homeostasisMichael D Aleo, Jiri Aubrecht, Paul D Bonin, et al.
British Journal of Pharmacology|December 8, 2017
Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA<sub>A</sub> receptor positive allosteric modulator PF-06372865Sarah A Nickolls, Rachel Gurrell, Guido van Amerongen, et al.
Pageof 2